Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 03843E104 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Bass Edward P
13G
|
7.5% |
10/7/2026
Event 10/7/2026
|
|
| Bass Edward P | 7.5% | ||
| Thru Line L.P. | 6.3% | ||
|
Bratton Douglas K
13G/A
Amendment 5
|
0.6% |
10/7/2026
Event 10/7/2026
|
|
| Bratton Douglas K | 0.6% | ||
| MonoLine RX II, L.P. | 0% | ||
| MonoLine RX III, L.P. | 0% | ||
| MonoLine RX, L.P. | 0% | ||
| MonoLine Partners, L.P. | 0% | ||
| MonoSol Rx Genpar, L.P. | 0% | ||
| Bratton Capital Management, L.P. | 0.3% | ||
| Bratton Capital Inc. | 0.3% | ||
| Bratton Family Partners L.P. | 0% | ||
| BlackRock, Inc. 13G/A Amendment 2 | 6.4% |
7/27/2026
Event 6/30/2026
|
|
|
RTW Investments, LP
13G
|
5.2% |
11/14/2025
Event 9/30/2025
|
|
| RTW Investments, LP | 5.2% | ||
| Roderick Wong | 5.2% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 5.3% |
10/17/2025
Event 9/30/2025
|
|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 1
|
2.9% |
2/14/2025
Event 12/31/2024
|
|
| Venrock Healthcare Capital Partners III, L.P. | 2.9% | ||
| VHCP Co-Investment Holdings III, LLC | 2.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 2.9% | ||
| VHCP Management III, LLC | 2.9% | ||
| VHCP Management EG, LLC | 2.9% | ||
| Nimish Shah | 2.9% | ||
| Bong Y Koh | 2.9% | ||
|
Bratton Douglas K
13G/A
Amendment 4
|
11.1% |
2/13/2025
Event 12/31/2024
|
|
| Bratton Douglas K | 11.1% | ||
| MonoLine RX II, L.P. | 3.8% | ||
| MonoLine RX III, L.P. | 2.9% | ||
| MonoLine RX, L.P. | 1.9% | ||
| MonoLine Partners, L.P. | 2.1% | ||
| MonoSol Rx Genpar, L.P. | 0.1% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 13 | 844 k | $3.91 M |
| 2026 Q2 | 196 | 72.0 M | $301 M |
| 2026 Q1 | 187 | 71.9 M | $299 M |
| 2025 Q4 | 194 | 72.3 M | $467 M |
| 2025 Q3 | 161 | 66.5 M | $372 M |
| 2025 Q2 | 124 | 48.0 M | $159 M |
| 2025 Q1 | 127 | 44.3 M | $131 M |
| 2024 Q4 | 122 | 43.4 M | $154 M |
| 2024 Q3 | 125 | 46.8 M | $237 M |
| 2024 Q2 | 105 | 43.1 M | $112 M |
| 2024 Q1 | 107 | 41.8 M | $178 M |
| 2023 Q4 | 65 | 23.9 M | $48.3 M |
| 2023 Q3 | 53 | 22.9 M | $21.5 M |
| 2023 Q2 | 58 | 19.1 M | $31.5 M |
| 2023 Q1 | 38 | 14.9 M | $17.0 M |
| 2022 Q4 | 41 | 15.0 M | $13.6 M |
| 2022 Q3 | 47 | 15.9 M | $18.7 M |
| 2022 Q2 | 48 | 16.7 M | $10.8 M |
| 2022 Q1 | 57 | 15.5 M | $40.7 M |
| 2021 Q4 | 63 | 16.4 M | $63.6 M |
| 2021 Q3 | 52 | 14.8 M | $64.4 M |
| 2021 Q2 | 65 | 15.6 M | $62.0 M |
| 2021 Q1 | 72 | 16.6 M | $86.4 M |
| 2020 Q4 | 71 | 19.2 M | $103 M |
| 2020 Q3 | 67 | 19.9 M | $96.5 M |
| 2020 Q2 | 63 | 18.5 M | $90.0 M |
| 2020 Q1 | 44 | 16.0 M | $35.0 M |
| 2019 Q4 | 58 | 17.5 M | $102 M |
| 2019 Q3 | 36 | 13.6 M | $43.2 M |
| 2019 Q2 | 41 | 14.5 M | $61.0 M |
| 2019 Q1 | 50 | 14.4 M | $99.6 M |
| 2018 Q4 | 38 | 14.4 M | $90.8 M |
| 2018 Q3 | 46 | 16.1 M | $282 M |